Abstract:Background: Chronic hypoxia-induced epithelial-to-mesenchymal transition (EMT) is a crucial process in renal fibrogenesis. Egr-1, as a transcription factor, has been proven to be important in promoting EMT. However, whether it functions in hypoxia-induced renal tubular EMT has not been fully elucidated. Methods: Egr-1 were detected at mRNA and protein levels by qPCR and Western blot analysis respectively after renal epithelial cells were subjected to hypoxia treatment. Meanwhile, EMT phenotype was also observed through identification of relevant EMT-specific markers. siRNA was used to knock down Egr-1 expression and subsequent changes were observed. Specific PKC and MAPK/ERK inhibitors were employed to determine the molecular signaling pathway involved in Egr-1-mediated EMT phenotype. In vivo assays using rat remnant kidney model were used to validate the in vitro results. Furthermore, Egr-1 expression was examined in the samples of CKD patients with the clinical relevance revealed. Results: Hypoxia treatment enhanced the mRNA and protein levels of Egr-1 in HK-2 cells, which was accompanied by a reduced expression of the epithelial marker E-cadherin and an enhanced expression of the mesenchymal marker Fsp-1. Downregulation of Egr-1 with siRNA reversed hypoxia-induced EMT. Using the specific inhibitors to protein kinase C (calphostin C) or MAPK/ERK (PD98059), we identified that hypoxia induced Egr-1 expression through the PKC/ERK pathway. In addition, the upregulation of Egr-1 raised endogenous Snail levels, and the downregulation of Snail inhibited Egr-1-mediated EMT in HK-2 cells. Through in vivo assays using rat remnant kidney and CKD patients' kidney tissues, we found that Egr-1 and Snail were overexpressed in tubular epithelial cells with EMT. Conclusion: Egr-1 may be an important regulator of the development of renal tubular EMT induced by hypoxia through the PKC/ERK pathway and the activation of Snail. Targeting Egr-1 expression or activity might be a novel therapeutic strategy to control renal fibrosis.

Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease

Renal Fibrosis and Epithelial-Mesenchymal Transition

The role of macrophages in fibrosis of chronic kidney disease

Renal fibrosis: New insights into the pathogenesis and therapeutics

New Insights Into the Role and Mechanism of Partial Epithelial-Mesenchymal Transition in Kidney Fibrosis

Role of mitochondria in pathogenesis and therapy of renal fibrosis

Epithelial–mesenchymal plasticity in kidney fibrosis

Emerging Roles Of Long Non-Coding Rnas In Renal Fibrosis

TGF-β-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases

The Role of the Macrophage-to-myofibroblast Transition in Renal Fibrosis

The origin of interstitial myofibroblasts in chronic kidney disease

WNT-dependent interaction between inflammatory fibroblasts and FOLR2+ macrophages promotes fibrosis in chronic kidney disease

Targeted Inhibition of Endoplasmic Reticulum Stress: New Hope for Renal Fibrosis

Epidermal growth factor receptor activation is essential for kidney fibrosis development

Metabolism at the crossroads of inflammation and fibrosis in chronic kidney disease

Epithelial-to-Mesenchymal Transition in Diabetic Nephropathy: Fact or Fiction?

Egr-1 mediates chronic hypoxia-induced renal interstitial fibrosis via the PKC/ERK pathway

Defining Therapeutic Targets for Renal Fibrosis: Exploiting the Biology of Pathogenesis

Enhancer of zeste homolog 2 promotes renal fibrosis after acute kidney injury by inducing epithelial-mesenchymal transition and activation of M2 macrophage polarization

Fibrosis in Chronic Kidney Disease: Pathogenesis and Consequences

The contribution of bone marrow-derived cells to the development of renal interstitial fibrosis